Delivers Second-Quarter Net Revenues of $15.423 Billion, an Increase of 6.6 Percent on a Reported Basis or 6.5 Percent on an Operational Basis "AbbVie delivered another outstanding quarter with strong ...

DelveInsight's KIT Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient ...

Skin cancer is caused by DNA damage in skin cells. The most common source of that damage is ultraviolet radiation from the ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...